摘要
目的 研究吡格列酮二甲双胍联合二肽基肽酶-4(DPP4)抑制剂对2型糖尿病的患者血糖控制及体态的影响。方法 选取2019年8月至2021年5月本院收治的116例2型糖尿病患者作为此次研究对象,并采用随机数字表法将其分为单一组(吡格列酮二甲双胍)、联合组(吡格列酮二甲双胍联合DPP4抑制剂),每组58例。比较2组治疗前和治疗3个月的血糖水平[空腹血糖(FBG)、餐后2 h血糖(2h PBG)、糖化血红蛋白(HbA1c)]、胰岛素抵抗指数(HOMA-IR)、体态[体重指数(BMI)、腰围、臀围]、氧化应激指标[丙二醛(MDA)、谷胱肽过氧化物酶(GSH-Px)、脂质过氧化氢(LHP)]以及不良反应发生率。结果 治疗3个月,联合组FBG、2hPBG、糖化血红蛋白(HbA1c)水平均低于单一组(P<0.05);联合组的HOMA-IR低于单一组(P<0.05),而2组的BMI、腰围、臀围比较差异无统计学意义(P>0.05);联合组的MDA、LHP水平均低于单一组,其GSH-Px水平高于单一组(P<0.05);在不良反应发生率方面,2组比较差异无统计学意义(P>0.05)。结论 在2型糖尿病患者中采用吡格列酮二甲双胍联合DPP4抑制剂治疗,能有效降低患者的血糖,减轻机体氧化应激反应,降低胰岛素抵抗,且不会对患者体态造成影响,无明显不良反应增加,安全性高。
Objective Objective To study the efficacy of pioglitazone metformin plus dipeptidyl peptidase 4(DPP4) inhibitor on blood glucose and posture of patients with type 2 diabetes mellitus(T2DM).Methods T2DM patients(n=116) treated in our hospital from August 2019 to May 2021 were randomized 1∶1 ratio using number table to receive Pioglitazone metformin(single group) or pioglitazone metformin + DPP4 inhibitors(combined group) for three months.The key observation was before treatment and 3-month blood glucose levels [fasting blood glucose(FBG), 2h postprandial blood glucose(2h PBG), glycated hemoglobin(HbA1c)], homeostasis model assessment for insulin resistance(HOMA-IR), body posture [body mass index(BMI), waist circumference(WC), hip circumference(HC)], oxidative stress indicators [malondialdehyde(MDA), glutathione peroxidase(GSH-PX), lipid hydrogen peroxide(LHP)] and incidence of adverse reactions.Results The levels of FBG, 2hPBG and HbA1c in combined group on month 3 of post-treatment were lower than those in single group(P<0.05).Homa-IR in the combined group was lower than that in the single group(P<0.05), while there were no significant differences in BMI, WC and HC between the two groups(P>0.05).The levels of MDA and LHP in combined group were lower than those in single group, and the levels of GSH-Px in combined group were higher than that in single group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion For T2DM patients, pioglitazone metformin + DPP4 inhibitor can effectively reduce blood glucose, restrain oxidative stress, decrease insulin resistance, not affect posture, with no obvious adverse reactions and high safety.
作者
杨莉
张大伟
YANG Li;ZHANG Dawei(Department of Endocrinology,Funan County People’s Hospital,Anhui,Funan 236300,China)
出处
《河北医药》
CAS
2022年第23期3626-3629,共4页
Hebei Medical Journal
关键词
2型糖尿病
吡格列酮二甲双胍
DPP4抑制剂
血糖控制
体态
不良反应
type 2 diabetes mellitus
pioglitazone metformin
DPP4 inhibitor
blood glucose control
posture
adverse reactions
